Apollomics, Inc. (APLM) NASDAQ
15.45
-0.45(-2.83%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
15.45
-0.45(-2.83%)
Currency In USD
| Previous Close | 15.9 |
| Open | 15.5 |
| Day High | 15.5 |
| Day Low | 15.45 |
| 52-Week High | 42.12 |
| 52-Week Low | 3.66 |
| Volume | 1,108 |
| Average Volume | 7,840 |
| Market Cap | 17.05M |
| PE | -2.04 |
| EPS | -7.57 |
| Moving Average 50 Days | 16.52 |
| Moving Average 200 Days | 15.83 |
| Change | -0.45 |
Apollomics Announces Settlement of Cayman Litigation
GlobeNewswire Inc.
Nov 19, 2025 10:38 PM GMT
FOSTER CITY, Calif., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”) (Nasdaq: APLM) announced today entering into a settlement agreement (the “Settlement Agreement” or the “Agreement”) with TWVC Goldlink Partners I
Apollomics Announces Changes to its Board of Directors and Composition of Committees
GlobeNewswire Inc.
Nov 18, 2025 4:00 AM GMT
FOSTER CITY, Calif., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a California-based late-stage clinical biopharmaceutical company, today announced the following update regarding changes to the C
Apollomics Announces Continued Listing on The Nasdaq Stock Market Following Hearing Cancellation
GlobeNewswire Inc.
Oct 15, 2025 6:36 PM GMT
Nasdaq Hearing Cancellation and Continued ListingFOSTER CITY, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a California based late-stage clinical biopharmaceutical company developing mult